In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Odyssey Pharmaceuticals Inc.

Division of Teva Pharmaceutical Industries Ltd.
www.odysseypharm.com

Latest From Odyssey Pharmaceuticals Inc.

Pliva: Two Steps Forward, One Step Back?

After a fervent US expanstion capped by the surprise $150 million licensing of Indevus OAB treatment Sanctura, proprietary ambitions at the Croatian generics play Pliva may be stalling. Sanctura sales have disappointed, illustrating again the challenges of taking a specialist approach to primary care marketing. Pliva's best bet may be to switch growth engines to its promising biogenerics portfolio.
BioPharmaceutical Strategy

PSA 2004: Looking to the Sustainable Middle

If the nominal theme of Windhover's 2004 Pharmaceutical Strategic Alliances conference was "transitions", the full subtext was "transitions to sustainability." Mid-sized players appear to have the best shot at sustainability in an environment where, increasingly, less differentiated, primary care blockbusters are out, and specialist products are in.
BioPharmaceutical Strategy

Pliva/Indevus: Moving Up the Value Chain

Pliva's not the obvious choice of US marketing partner for Indevus' overactive bladder drug Sanctura. With no primary care presence in the US, the company will likely face an uphill battle to commercialize the drug; more so given the stiff competition in OAB from some of the world's leading Big Pharma marketeers. Yet the deal's about more than success with Sanctura. It's about both parties moving up the value chain--Pliva into the US proprietary drugs arena and Indevus into sales and marketing.
BioPharmaceutical Strategy

Pliva: Europe is Not Enough

Buying Sobel Holdings makes Croatia's Pliva one of the first eastern European companies to buy into the US market. It's doing so cleverly, leveraging future revenues from its biggest product, azithromycin, to fund the deal, and executing it through a tax-efficient Hungarian subsidiary.
BioPharmaceutical United States
See All
Advertisement
Advertisement
UsernamePublicRestriction

Register